Year All202420232022 Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Nov 12, 2024 Read More Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference Nov 11, 2024 Read More Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares Sep 16, 2024 Read More Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering Sep 12, 2024 Read More Bicara Therapeutics Expands Board of Directors with Appointments of Mike Powell, Ph.D., and Christopher Bowden, M.D. Aug 15, 2024 Read More Bicara Therapeutics Reports Updated Interim Phase 1/1b Data of Ficerafusp Alfa (BCA101) in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Jun 27, 2024 Read More Bicara Therapeutics Expands Clinical Team with Appointments of Jeltje Schulten, M.D., MBA, as SVP of Clinical and Medical Affairs and Rita Dalal, MBBS, MPH, as VP of Clinical Development Mar 26, 2024 Read More Bicara Therapeutics to Participate in Upcoming March Investor Conferences Feb 27, 2024 Read More Bicara Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference Jan 02, 2024 Read More
Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Nov 12, 2024 Read More
Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares Sep 16, 2024 Read More
Bicara Therapeutics Expands Board of Directors with Appointments of Mike Powell, Ph.D., and Christopher Bowden, M.D. Aug 15, 2024 Read More
Bicara Therapeutics Reports Updated Interim Phase 1/1b Data of Ficerafusp Alfa (BCA101) in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Jun 27, 2024 Read More
Bicara Therapeutics Expands Clinical Team with Appointments of Jeltje Schulten, M.D., MBA, as SVP of Clinical and Medical Affairs and Rita Dalal, MBBS, MPH, as VP of Clinical Development Mar 26, 2024 Read More
Bicara Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference Jan 02, 2024 Read More
